Prostate CancerPhase 3NCT01368588
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study testing three-dimensional conformal radiotherapy, intensity modulated radiotherapy and Brachytherapy in people with Prostate Cancer, run by Radiation Therapy Oncology Group at 478 sites in 6 countries.
Trial summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy and Brachytherapy
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,590 participants
- Where
- 478 sitesin 6 countries
- Study dates
- Jul 2011to Jul 2031
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence as determined by one of the following combinations:
- Gleason score 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
- Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/ml -ORGleason score 6 + ≥ 50% (positive) biopsies + PSA < 50 ng/ml;
- Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/ml. Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are re-biopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure.
- History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.
- Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), (but not by nodal sampling, or dissection) within 90 days prior to registration.
- Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm. *No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (Na F PET/CT is an acceptable substitute).
- Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis. *Baseline serum PSA value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration.
- Study entry PSA should not be obtained during the following time frames: (1) 10- day period following prostate biopsy; (2) following initiation of hormonal therapy; (3) within 30 days after discontinuation of finasteride; (4) within 90 days after discontinuation of dutasteride.
- Zubrod Performance Status 0-1(unless otherwise specified);
- Age ≥ 18;
- CBC/differential obtained within 60 days prior to registration on study, with adequate bone marrow function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
- Platelets ≥ 100,000 cells/mm3;
- Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
- Patient must be able to provide study specific informed consent prior to study entry.
Trial locations and contacts
478 sites in 6 countries.
324 sites in 6 countries
United States300 sites
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
Texas Cancer Center
Abilene, Texas, 79606
Jefferson Abington Hospital
Abington, Pennsylvania, 19001
Bixby Medical Center
Adrian, Michigan, 49221
Summa Health System - Akron Campus
Akron, Ohio, 44304
Cleveland Clinic Akron General
Akron, Ohio, 44307
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
McFarland Clinic PC - Ames
Ames, Iowa, 50010
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Veteran's Administration Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Anne Arundel Medical Center
Annapolis, Maryland, 21401
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin, 54911
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Grady Health System
Atlanta, Georgia, 30303
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Piedmont Hospital
Atlanta, Georgia, 30309
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
University of Colorado Hospital
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, 93301
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Saint Agnes Hospital
Baltimore, Maryland, 21229
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
South Shore University Hospital
Bay Shore, New York, 11706
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
Texas Oncology PA Beaumont
Beaumont, Texas, 77702
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Southwestern Vermont Medical Center
Bennington, Vermont, 05201
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Billings Clinic Cancer Center
Billings, Montana, 59101
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Hartford HealthCare - Saint Vincent's Medical Center
Bridgeport, Connecticut, 06606
United Hospital Center
Bridgeport, West Virginia, 26330
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin, 53045
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
University of Vermont Medical Center
Burlington, Vermont, 05401
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Sands Cancer Center
Canandiaqua, New York, 14424
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Mercy San Juan Medical Center
Carmichael, California, 95608
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Saint Luke's Hospital
Cedar Rapids, Iowa, 52402
Mercy Hospital
Cedar Rapids, Iowa, 52403
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Geauga Hospital
Chardon, Ohio, 44024
Medical University of South Carolina
Charleston, South Carolina, 29425
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Erlanger Medical Center
Chattanooga, Tennessee, 37403
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Rush University Medical Center
Chicago, Illinois, 60612
Weiss Memorial Hospital
Chicago, Illinois, 60640
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital
Chicago, Illinois, 60657
Adventist Health Cancer Care Center Chico
Chico, California, 95973
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
GenesisCare USA - Clarkston
Clarkston, Michigan, 48346
McLaren Cancer Institute-Clarkston
Clarkston, Michigan, 48346
Case Western Reserve University
Cleveland, Ohio, 44106
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, 48038
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, 21044
John B Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Mary Bird Perkins Cancer Center - Covington
Covington, Louisiana, 70433
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Geisinger Medical Center
Danville, Pennsylvania, 17822
Beaumont Hospital - Dearborn
Dearborn, Michigan, 48124
Atlanta VA Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital
Decatur, Illinois, 62526
Broward Health North
Deerfield Beach, Florida, 33064
Texas Oncology - Denison Cancer Center
Denison, Texas, 75020
Porter Adventist Hospital
Denver, Colorado, 80210
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Ascension Saint John Hospital
Detroit, Michigan, 48236
Finley Hospital
Dubuque, Iowa, 52001
Saint Luke's Hospital of Duluth
Duluth, Minnesota, 55805
Northeast Radiation Oncology Center
Dunmore, Pennsylvania, 18512
Durham VA Medical Center
Durham, North Carolina, 27705
Duke University Medical Center
Durham, North Carolina, 27710
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Mayo Clinic Health System Eau Claire Hospital-Luther Campus
Eau Claire, Wisconsin, 54703
Shaw Cancer Center
Edwards, Colorado, 81632
Crossroads Cancer Center
Effingham, Illinois, 62401
AtlantiCare Surgery Center
Egg Harbor, New Jersey, 08234
University of Maryland Radiation Oncology Center at Union Hospital
Elkton, Maryland, 21921
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
Exeter Hospital
Exeter, New Hampshire, 03833
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Saint Anne's Hospital
Fall River, Massachusetts, 02721
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
GenesisCare USA - Farmington Hills
Farmington Hills, Michigan, 48334
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334
Beaumont Hospital - Farmington Hills
Farmington Hills, Michigan, 48336
Piedmont Fayette Hospital
Fayetteville, Georgia, 30214
Saint Francis Hospital
Federal Way, Washington, 98003
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
McLaren Cancer Institute-Flint
Flint, Michigan, 48532
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Radiation Oncology Associates PC
Fort Wayne, Indiana, 46804
Parkview Hospital Randallia
Fort Wayne, Indiana, 46805
Parkview Regional Medical Center
Fort Wayne, Indiana, 46845
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, 76104
Ascension Saint Francis - Reiman Cancer Center
Franklin, Wisconsin, 53132
Fresno Cancer Center
Fresno, California, 93720
Saint Agnes Medical Center
Fresno, California, 93720
Fox Chase Cancer Center Buckingham
Furlong, Pennsylvania, 18925
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
University of Texas Medical Branch
Galveston, Texas, 77555-0565
Central Care Cancer Center - Garden City
Garden City, Kansas, 67846
Saint Catherine Hospital
Garden City, Kansas, 67846
Tidelands Georgetown Memorial Hospital
Georgetown, South Carolina, 29440
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Arizona Breast Cancer Specialists-Gilbert
Gilbert, Arizona, 85297
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Three Rivers Community Hospital
Grants Pass, Oregon, 97527
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Marin General Hospital
Greenbrae, California, 94904
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Self Regional Healthcare
Greenwood, South Carolina, 29646
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Sentara Cancer Institute at Sentara CarePlex Hospital
Hampton, Virginia, 23666
Cherry Tree Cancer Center
Hanover, Pennsylvania, 17331
Sentara Rockingham Memorial Hospital Hahn Cancer Center
Harrisonburg, Virginia, 22801
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
The Radiation Oncology Center-Hilton Head/Bluffton
Hilton Head Island, South Carolina, 29926
Queen's Medical Center
Honolulu, Hawaii, 96813
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, 71913
Mary Bird Perkins Cancer Center - Houma
Houma, Louisiana, 70360
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77024
Ben Taub General Hospital
Houston, Texas, 77030
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Cleveland Clinic Cancer Center Independence
Independence, Ohio, 44131
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Baptist Medical Center South
Jacksonville, Florida, 32258
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, 72401
Freeman Health System
Joplin, Missouri, 64804
Jupiter Medical Center
Jupiter, Florida, 33458
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
University of Kansas Cancer Center
Kansas City, Kansas, 66160
North Kansas City Hospital
Kansas City, Missouri, 64116
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, 64128
The University of Kansas Cancer Center-South
Kansas City, Missouri, 64131
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Northwell Health/Center for Advanced Medicine
Lake Success, New York, 11042
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan, 48910
Sparrow Hospital
Lansing, Michigan, 48912
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan, 48446
Memorial Medical Center - Las Cruces
Las Cruces, New Mexico, 88011
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
UTMB Cancer Center at Victory Lakes
League City, Texas, 77573
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Sechler Family Cancer Center
Lebanon, Pennsylvania, 17042
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Tibor Rubin VA Medical Center
Long Beach, California, 90822
Longmont United Hospital
Longmont, Colorado, 80501
Los Angeles County-USC Medical Center
Los Angeles, California, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Cedars Sinai Medical Center
Los Angeles, California, 90048
McKee Medical Center
Loveland, Colorado, 80539
Lowell General Hospital
Lowell, Massachusetts, 01854
Central Georgia Gynecologic Oncology
Macon, Georgia, 31201
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, 56001
Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio, 44906
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Fremont - Rideout Cancer Center
Marysville, California, 95901
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Loyola University Medical Center
Maywood, Illinois, 60153
Texas Oncology-McAllen
McAllen, Texas, 78503
Texas Oncology-McKinney
McKinney, Texas, 75071
Providence Medford Medical Center
Medford, Oregon, 97504
Rogue Valley Medical Center
Medford, Oregon, 97504
Summa Health Medina Medical Center
Medina, Ohio, 44256
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin, 53097
Mercy UC Davis Cancer Center
Merced, California, 95340
Idaho Urologic Institute-Meridian
Meridian, Idaho, 83642
East Jefferson General Hospital
Metairie, Louisiana, 70006
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana, 70006
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, 44130
Middlesex Hospital
Middletown, Connecticut, 06457
Upper Delaware Valley Cancer Center
Milford, Pennsylvania, 18337
Ascension Southeast Wisconsin Hospital - Saint Joseph Campus
Milwaukee, Wisconsin, 53210
Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin, 53211
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Zablocki Veterans Administration Medical Center
Milwaukee, Wisconsin, 53295
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, 36688
Memorial Medical Center
Modesto, California, 95355
Monticello Cancer Center
Monticello, Minnesota, 55362
The Coleman Radiation Center-Carteret General Hospital
Morehead City, North Carolina, 28557
West Virginia University Healthcare
Morgantown, West Virginia, 26506
McLaren Cancer Institute-Macomb
Mount Clemens, Michigan, 48043
Virtua Memorial
Mount Holly, New Jersey, 08060
McLaren Cancer Institute-Central Michigan
Mount Pleasant, Michigan, 48858
Inspira Medical Center Mullica Hill
Mullica Hill, New Jersey, 08062
Intermountain Medical Center
Murray, Utah, 84107
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Touro Infirmary
New Orleans, Louisiana, 70115
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Helen F Graham Cancer Center
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Bon Secours DePaul Medical Center
Norfolk, Virginia, 23505
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Kaiser Permanente Oakland-Broadway
Oakland, California, 94611
West Texas Cancer Center
Odessa, Texas, 79761
McKay-Dee Hospital Center
Ogden, Utah, 84403
Ogden Regional Medical Center
Ogden, Utah, 84405
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Olathe Health Cancer Center
Olathe, Kansas, 66061
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Saint Charles Hospital
Oregon, Ohio, 43616
Orlando Health Cancer Institute
Orlando, Florida, 32806
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, 54904
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, 42303
McLaren Cancer Institute-Owosso
Owosso, Michigan, 48867
Cancer Center of Putnam
Palatka, Florida, 32177
Desert Regional Medical Center
Palm Springs, California, 92262
Palo Alto Medical Foundation Health Care
Palo Alto, California, 94301
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304
Parker Adventist Hospital
Parker, Colorado, 80138
University Hospitals Parma Medical Center
Parma, Ohio, 44129
Singing River Hospital
Pascagoula, Mississippi, 39581
Arizona Center for Cancer Care-Peoria
Peoria, Arizona, 85381
Canada18 sites
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
QEII Health Sciences Centre/Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9
BCCA-Cancer Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
London Regional Cancer Program
London, Ontario, N6A 4L6
CHUM - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1
McGill University Department of Oncology
Montreal, Quebec, H2W 1S6
CHUM - Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4
The Research Institute of the McGill University Health Centre (MUHC)
Montreal, Quebec, H3H 2R9
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, L3Y 2P9
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, J1H 5N4
Doctor H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, A1B 3V6
BCCA-Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
Israel2 sites
Rabin Medical Center
Petah Tikva, 49100
Chaim Sheba Medical Center
Tel HaShomer, 52621
Singapore2 sites
National University Hospital Singapore
Singapore, 119074
National Cancer Centre Singapore
Singapore, 169610
About this study
Official title: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
Read the detailed description
OBJECTIVES:
Primary
- Demonstrate that prophylactic, neoadjuvant androgen-deprivation therapy (NADT) combined with whole-pelvic radiation therapy (WPRT) improves overall survival (OS) compared with NADT combined with prostate and seminal vesicle radiation therapy (RT), with both arms receiving a high-dose prostate boost delivered by intensity-modulated RT (IMRT), external-beam RT (EBRT), high-dose-rate (HDR) brachytherapy, or permanent prostate implant (PPI).
Secondary
- Demonstrate that prophylactic WPRT improves biochemical control.
- Determine the distant metastasis (DM)-free survival.
- Determine the cause-specific survival (CSS).
- Compare acute and late treatment-adverse events between patients receiving NADT and WPRT versus NADT, P, and SV RT.
- Determine whether health-related quality of life (HRQOL), as measured by the Expanded Prostate Cancer Index Composite (EPIC), significantly worsens with increasing aggressiveness of treatment (i.e., Arm 2, NADT + WPRT).
- Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (PROMIS Fatigue Short Form) from baseline to last week of treatment, and a greater increase in circulating inflammatory markers (IL-1, IL-1ra, IL-6, tumor necrosis factor (TNF)-alpha, and C-reactive protein).
- Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
- Determine whether changes in fatigue from baseline to the next three time points (week prior to RT, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.
- Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.
OUTLINE: This is a multicenter study. Patients are stratified according to moderate- to high-risk groups as listed in the Disease Characteristics of this abstract, type of radiotherapy boost (IMRT vs brachytherapy [Low-dose rate (LDR) using PPI or HDR]), and duration of androgen-deprivation therapy (short-term [4-6 months] vs long-term [32 months]). Patients are randomized to 1 of 2 treatment arms.
All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy comprising leuprolide acetate, goserelin acetate, buserelin, triptorelin, or degarelix subcutaneously (SC) or intramuscularly (IM) every 1 to 3 months beginning 2 months prior to radiotherapy and continuing for 4-6 or 32 months.
Radiotherapy begins within 8 weeks after beginning LHRH agonist/antagonist injection.
Patients may undergo blood and urine sample collection for correlative studies. Primary tumor tissue samples may also be collected.
Patients may complete the Expanded Prostate Cancer Index Composite (EPIC), the PROMIS-Fatigue Short Form, and the EuroQol (EQ-5D) quality-of-life (QOL) questionnaires at baseline and periodically during treatment. Patients who participate in the QOL portion of the study must also agree to periodic blood collection.
After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then yearly thereafter.
- Conditions
- Prostate Cancer
- Being tested
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
- Keywords
- adenocarcinoma of the prostate, stage I prostate cancer, stage IIA prostate cancer, stage IIB prostate cancer, stage III prostate cancer
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
three-dimensional conformal radiotherapyRadiation
Daily fractions
intensity modulated radiotherapyRadiation
Daily fractions
BrachytherapyRadiation
Implant
Anti-androgenDrug
Tablet
luteinizing hormone-releasing hormone (LHRH) agonist or antagonistDrug
Injection
| Study group | Role | What they receive |
|---|---|---|
| Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1) | Active comparator | Participants receive androgen deprivation therapy (ADT), consisting of an oral anti androgen plus a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, for a total duration of 4, 6, or 32 months. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the prostate and entire seminal vesicles, delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost to the prostate and proximal seminal vesicles follows, using either IMRT (34.2 Gy in 19 fractions, with protocol specified dose reduction options when indicated) or brachytherapy delivered as low dose rate (LDR) or high dose rate (HDR) implant per protocol. Receives: Radiation: three-dimensional conformal radiotherapy; Radiation: intensity modulated radiotherapy; Radiation: Brachytherapy; Drug: Anti-androgen; Drug: luteinizing hormone-releasing hormone (LHRH) agonist or antagonist |
| Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) | Experimental | Participants receive ADT as in Arm 1. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the whole pelvis-including prostate, seminal vesicles, and pelvic lymph nodes-delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost is then administered as specified for Arm 1. Receives: Radiation: three-dimensional conformal radiotherapy; Radiation: intensity modulated radiotherapy; Radiation: Brachytherapy; Drug: Anti-androgen; Drug: luteinizing hormone-releasing hormone (LHRH) agonist or antagonist |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Alive (Overall Survival)
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Measured: From randomization to death or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Secondary outcomes (9)
Percent of Participants Who Died Due to Prostate Cancer
Prostate cancer death rates were estimated using the cumulative incidence method, treating death due to other causes as a competing risk, and otherwise censoring participants alive at time of analysis.
Measured: From randomization to death due to prostate cancer or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Percentage of Participants With Distant Metastasis
Distant metastasis rates were estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive without distant metastasis at time of analysis.
Measured: From date of randomization to distant metastasis, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Percentage of Participants With Biochemical Failure
Biochemical failure is defined as a rise in prostate-specific antigen (PSA) of ≥2.0 ng/mL above the post-treatment PSA nadir following radiation therapy for prostate cancer (Phoenix definition). Biochemical failure rates were estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive without biochemical failure at time of analysis.
Measured: From date of randomization to the date of biochemical failure, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Number of Participants by Highest Grade Acute Adverse Event Reported
Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity as follows: 1 = mild, 2
= moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Acute adverse events are defined as those occurring within 30 days after the completion of radiation therapy. RT begins approximately weeks 8-10 after starting protocol therapy and ends approximately weeks 19-22, depending on boost technique. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
Measured: From protocol treatment start date to 30 days from completion of radiation therapy. RT begins approximately weeks 8-10 after starting protocol therapy and ends approximately weeks 19-22, depending on boost technique.
Number of Participants by Highest Grade Late Adverse Event Reported
Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity as follows: 1 = mild, 2
= moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Late adverse events are defined as occurring ≥ 30 days after end of RT (approximately weeks 19-22, depending on boost technique). Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
Measured: From 30 days after completion of radiation therapy (approximately weeks 19-22, depending on boost technique) to highest grade late adverse event. Median follow-up at time of analysis was 6.7 years.
EPIC-26 Urinary Bowel Domain Score Change From Baseline at 6 Months
The Expanded Prostate Cancer Index Composite-26 (EPIC-26) measures health-related quality of life in men with prostate cancer across urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal domains. Possible scores range from 0 to 100, with higher scores indicating better quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.
Measured: Baseline and 6 months after the end of RT, approximately 19-22 weeks, depending on boost technique.
EPIC-26 Urinary Irritative/Obstructive Subscore Change From Baseline at 6 Months
The Expanded Prostate Cancer Index Composite-26 (EPIC-26) measures health-related quality of life in men with prostate cancer across urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal domains. Possible scores range from 0 to 100, with higher scores indicating better quality of life. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.
Measured: Baseline and 6 months after the end of RT, approximately 19-22 weeks, depending on boost technique.
PROMIS Fatigue Score Change From Baseline Line at Last Week of Radiation Treatment
The Patient-Reported Outcome Measurement Information System (PROMIS) fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
Measured: Baseline and last week of radiation treatment, approximately 19-22 weeks, depending on boost technique.
Quality Adjusted Life Years (QALYs)
Quality adjusted life years is calculated as the weighted sum of the number of years spent in different health states. The weight value is a utility score between 0 (worst health state) and 1 (best health state) derived from the EQ-5D questionnaire, designed to describe and value health based on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Measured: Baseline; the week prior to radiation therapy (RT); the last week of RT; 6 months, 1 year, and 5 years after RT. RT begins about weeks 8-10 after starting protocol therapy and ends about weeks 19-22, depending on boost technique.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2011 (estimated)
- Study startJul 2011
- Primary completion17 Apr 2025
- Study completionJul 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,590 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), NRG Oncology
- Responsible party
- Sponsor
- Investigators
- Mack Roach, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01368588
- Sponsor's protocol ID
- RTOG-0924
- Other IDs
- CDR0000701128, NCI-2011-02674
- Status last verified
- Apr 2026
- First submitted
- 7 Jun 2011
- Last updated
- 8 May 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
- ClinicalTrials.gov ID
- NCT01368588
- Acronym / sponsor ID
- RTOG-0924
- Conditions
- Prostate Cancer
- Keywords
- adenocarcinoma of the prostate, stage I prostate cancer, stage IIA prostate cancer, stage IIB prostate cancer, stage III prostate cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,590 participants (actual)
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI), NRG Oncology
- Study start
- Jul 2011 (actual)
- Primary completion
- 17 Apr 2025 (actual)
- Study completion
- Jul 2031 (estimated)
- First posted
- 8 Jun 2011 (estimated)
- Results
- Posted 8 May 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
Detailed description
OBJECTIVES:
Primary
- Demonstrate that prophylactic, neoadjuvant androgen-deprivation therapy (NADT) combined with whole-pelvic radiation therapy (WPRT) improves overall survival (OS) compared with NADT combined with prostate and seminal vesicle radiation therapy (RT), with both arms receiving a high-dose prostate boost delivered by intensity-modulated RT (IMRT), external-beam RT (EBRT), high-dose-rate (HDR) brachytherapy, or permanent prostate implant (PPI).
Secondary
- Demonstrate that prophylactic WPRT improves biochemical control.
- Determine the distant metastasis (DM)-free survival.
- Determine the cause-specific survival (CSS).
- Compare acute and late treatment-adverse events between patients receiving NADT and WPRT versus NADT, P, and SV RT.
- Determine whether health-related quality of life (HRQOL), as measured by the Expanded Prostate Cancer Index Composite (EPIC), significantly worsens with increasing aggressiveness of treatment (i.e., Arm 2, NADT + WPRT).
- Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (PROMIS Fatigue Short Form) from baseline to last week of treatment, and a greater increase in circulating inflammatory markers (IL-1, IL-1ra, IL-6, tumor necrosis factor (TNF)-alpha, and C-reactive protein).
- Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
- Determine whether changes in fatigue from baseline to the next three time points (week prior to RT, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.
- Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.
OUTLINE: This is a multicenter study. Patients are stratified according to moderate- to high-risk groups as listed in the Disease Characteristics of this abstract, type of radiotherapy boost (IMRT vs brachytherapy [Low-dose rate (LDR) using PPI or HDR]), and duration of androgen-deprivation therapy (short-term [4-6 months] vs long-term [32 months]). Patients are randomized to 1 of 2 treatment arms.
All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy comprising leuprolide acetate, goserelin acetate, buserelin, triptorelin, or degarelix subcutaneously (SC) or intramuscularly (IM) every 1 to 3 months beginning 2 months prior to radiotherapy and continuing for 4-6 or 32 months.
Radiotherapy begins within 8 weeks after beginning LHRH agonist/antagonist injection.
Patients may undergo blood and urine sample collection for correlative studies. Primary tumor tissue samples may also be collected.
Patients may complete the Expanded Prostate Cancer Index Composite (EPIC), the PROMIS-Fatigue Short Form, and the EuroQol (EQ-5D) quality-of-life (QOL) questionnaires at baseline and periodically during treatment. Patients who participate in the QOL portion of the study must also agree to periodic blood collection.
After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then yearly thereafter.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1) | Active comparator | Radiation: three-dimensional conformal radiotherapy, Radiation: intensity modulated radiotherapy, Radiation: Brachytherapy, Drug: Anti-androgen, Drug: luteinizing hormone-releasing hormone (LHRH) agonist or antagonistParticipants receive androgen deprivation therapy (ADT), consisting of an oral anti androgen plus a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, for a total duration of 4, 6, or 32 months. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the prostate and entire seminal vesicles, delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost to the prostate and proximal seminal vesicles follows, using either IMRT (34.2 Gy in 19 fractions, with protocol specified dose reduction options when indicated) or brachytherapy delivered as low dose rate (LDR) or high dose rate (HDR) implant per protocol. |
| Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) | Experimental | Radiation: three-dimensional conformal radiotherapy, Radiation: intensity modulated radiotherapy, Radiation: Brachytherapy, Drug: Anti-androgen, Drug: luteinizing hormone-releasing hormone (LHRH) agonist or antagonistParticipants receive ADT as in Arm 1. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the whole pelvis-including prostate, seminal vesicles, and pelvic lymph nodes-delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost is then administered as specified for Arm 1. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| three-dimensional conformal radiotherapyDaily fractions | Radiation | Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1), Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) |
| intensity modulated radiotherapyDaily fractions | Radiation | Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1), Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) |
| BrachytherapyImplant | Radiation | Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1), Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) |
| Anti-androgenTablet | Drug | Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1), Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) |
| luteinizing hormone-releasing hormone (LHRH) agonist or antagonistInjection | Drug | Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1), Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2) |
Primary outcome
Percentage of Participants Alive (Overall Survival)
Time frame: From randomization to death or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
9 secondary outcomes
Percent of Participants Who Died Due to Prostate Cancer
Time frame: From randomization to death due to prostate cancer or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Percentage of Participants With Distant Metastasis
Time frame: From date of randomization to distant metastasis, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Percentage of Participants With Biochemical Failure
Time frame: From date of randomization to the date of biochemical failure, death, or last follow-up, whichever occurs first. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.
Number of Participants by Highest Grade Acute Adverse Event Reported
Time frame: From protocol treatment start date to 30 days from completion of radiation therapy. RT begins approximately weeks 8-10 after starting protocol therapy and ends approximately weeks 19-22, depending on boost technique.
Number of Participants by Highest Grade Late Adverse Event Reported
Time frame: From 30 days after completion of radiation therapy (approximately weeks 19-22, depending on boost technique) to highest grade late adverse event. Median follow-up at time of analysis was 6.7 years.
EPIC-26 Urinary Bowel Domain Score Change From Baseline at 6 Months
Time frame: Baseline and 6 months after the end of RT, approximately 19-22 weeks, depending on boost technique.
EPIC-26 Urinary Irritative/Obstructive Subscore Change From Baseline at 6 Months
Time frame: Baseline and 6 months after the end of RT, approximately 19-22 weeks, depending on boost technique.
PROMIS Fatigue Score Change From Baseline Line at Last Week of Radiation Treatment
Time frame: Baseline and last week of radiation treatment, approximately 19-22 weeks, depending on boost technique.
Quality Adjusted Life Years (QALYs)
Time frame: Baseline; the week prior to radiation therapy (RT); the last week of RT; 6 months, 1 year, and 5 years after RT. RT begins about weeks 8-10 after starting protocol therapy and ends about weeks 19-22, depending on boost technique.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mack Roach, MD principal investigator
University of California, San Francisco
478 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing three-dimensional conformal radiotherapy, intensity modulated radiotherapy and Brachytherapy in people with Prostate Cancer, run by Radiation Therapy Oncology Group at 478 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 478 sites in United States, Canada, Israel, Singapore, Hong Kong and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 May 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Alive (Overall Survival) (time frame: From randomization to death or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.